Wordt geladen...
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
On August 26, 2011, crizotinib received accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by a test approved by the U.S. Food and Drug Administration (FDA). Approval was based on two single-arm t...
Bewaard in:
| Hoofdauteurs: | , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
AlphaMed Press
2014
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4201002/ https://ncbi.nlm.nih.gov/pubmed/25170012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0241 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|